Pfizer’s full-year revenues grow 23%, top $100B — UniQure nabs another gene therapy for ALS — AstraZeneca, Novo Nordisk and Sanofi score 340B-related appeals court win over HHS -- See more on our front page news http://bit.ly/w28kSd #pfizer #earnings #als #340B #hhs #astrazeneca #novonordisk #sanofi #drugdiscounts #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
#pfizer #earnings #ALS #340b #hhs #astrazeneca #novonordisk #Sanofi #drugdiscounts #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
The WSJ story on #340B earlier this week was a must-read, but the
340B Report
wrap of reactions is just as illuminating, in its own way.
The way 340B is being discussed has shifted, and the piece shows that covered entities haven't really adapted.
Now the WSJ is turning both barrels on hospitals re: #340B. This should be interesting.
https://www.wsj.com/articles/340b-drug-discounts-hospitals-low-income-federal-program-11671553899